Smith & Nephew Stock Price, News & Analysis

Smith+Nephew (NYSE: SNN) has announced the upcoming launch of ARIA Home PT, a remote physical therapy module for its ARIA digital care management platform, set for early 2021. This module includes a virtual coaching system utilizing 3D motion capture technology, aiming to enhance patient recovery and expand access to post-acute care. Telehealth functionalities will follow soon after. The initiative is part of Smith+Nephew's investment in its Positive Connections program, addressing the growing demand for digital health solutions.

Smith+Nephew (NYSE:SNN) has been awarded Most Innovative at the 2020 Gartner Communications Awards for its T.I.M.E. clinical decision support tool (CDST), which addresses the lack of consistent wound assessment practices among specialists. Developed through collaboration with international experts, the tool aims to improve clinical outcomes by standardizing care delivery. The campaign has seen significant customer engagement, generating multiple publications and a consensus document by the World Union of Wound Healing Societies. This recognition highlights Smith+Nephew’s commitment to enhancing patient care and stakeholder engagement.

Smith+Nephew (NYSE:SNN) has partnered with Avail Medsystems to implement remote collaboration services in operating rooms. This innovative approach allows healthcare professionals to support procedures without being physically present, enhancing efficiency in hospitals and ASCs where space is limited. The Avail System features HD cameras and a split-screen display for real-time interaction. Smith+Nephew aims to improve surgical education and access to expertise while reducing capital investments. This initiative aligns with their mission to enhance medical technology and demonstrates adaptability in a changing healthcare environment.

Smith+Nephew has launched the HEALICOIL KNOTLESS Suture Anchor, enhancing its Advanced Healing Solutions portfolio for rotator cuff repairs. This innovative product utilizes a unique open architecture design with REGENESORB Material, promoting faster bone healing and less foreign material in the body. Clinical insights suggest superior healing at the tendon-bone interface. The company aims to redefine healing potential, reinforcing its commitment to patient recovery. Annual sales reached $5.1 billion in 2019, with a strong presence in over 100 countries.

Smith+Nephew (NYSE:SNN) has launched its NOVOSTITCH PRO Meniscal Repair System in Europe following CE mark certification. This innovative system aims to address the needs of around 600,000 European patients annually suffering from meniscal tears, a common orthopedic injury. Traditionally, many patients undergo partial or complete meniscectomy, increasing their risk of osteoarthritis. The NOVOSTITCH PRO system allows surgeons to perform repairs more effectively in tight joint compartments. Initial clinical experiences have been positive, with surgeons highlighting its versatility and potential to improve patient outcomes.

Smith+Nephew (NYSE: SNN) launched ARIA, a digital platform aimed at enhancing patient care by improving communication between patients and providers during surgical episodes. Powered by the Real Intelligence ecosystem, ARIA helps reduce recovery times, minimize costs, and gather Patient Reported Outcome Measures (PROMs). The platform integrates secure communication and customizable pathways, leading to actionable data for surgery centers and enhancing efficiencies. Prior technology acquisitions are foundational to ARIA's capabilities, including a documented 45% reduction in readmissions in previous implementations.

On July 28, 2020, Smith+Nephew (NYSE: SNN) launched the RI.HIP NAVIGATION technology for total hip arthroplasty (THA). This system enhances surgical accuracy through patient-specific component alignment, following the acquisition of Brainlab's Orthopaedic Joint Reconstruction business in May 2019. The POLAR3™ Primary Total Hip System, known for delivering a 98% survivorship rate at 8 years, integrates with Brainlab's platform used in over 500 hospitals. This innovation received FDA clearance and CE Mark certification, aiming to improve patient outcomes while being cost-efficient for hospitals and ASCs.

Smith+Nephew (NYSE:SNN) announced a significant milestone with over two million patients treated using their OXINIUM Technology, a proprietary oxidized zirconium alloy for hip and knee replacements. OXINIUM offers a combination of metal strength and ceramic wear resistance, enhancing durability and performance in joint applications.

Clinical data highlights OXINIUM's superiority, including 29% reduction in revision risk post arthroplasty and results from 45 million cycles in wear testing. This technology underpins advanced products like POLAR3 and JOURNEY II, reflecting Smith+Nephew's commitment to innovation in orthopaedics.

Smith+Nephew (NYSE:SNN) announced on June 16, 2020, that its REGENETEN Bioinductive Implant has received CE Mark certification, allowing its use in key European markets. This implant has been pivotal in over 40,000 procedures in the US, enhancing approaches to rotator cuff surgery. The implant, which aids natural healing by promoting tendon-like tissue growth, will be available for over 310,000 annual rotator cuff procedures in Europe, a market worth approximately $175 million. The company aims to transform patient outcomes with this innovative technology.